As Jounce’s Vopratelimab Fails, Door Opens For LILRB2 Inhibitor JTX-8064

 
• By Alaric DeArment

Vopratelimab is the second major ICOS agonist program to fail since GSK halted studies of feladilimab last year, but an analyst pinned higher hopes on JTX-8064.

Announcing SELECT's failure gives Jounce the chance to shift gears to JTX-8064 • Source: Shutterstock

More from Clinical Trials

More from R&D